Cray Opens New Markets For Supercomputers

Out of the Minneapolis suburbs they swarm in business suits, popping up at technical conferences and slowly picking the brains of the best scientists in a given field. Reconnaissance complete, they return home to sharpen their plans. A target is singled out for the kill—and if all goes well, Cray Research Inc. has sold another multimillion dollar supercomputer. This is the company’s newest sales hit team, comprising 60 of the company’s best salespeople, engineers, and scientis

Written byRobert Buderi
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Out of the Minneapolis suburbs they swarm in business suits, popping up at technical conferences and slowly picking the brains of the best scientists in a given field. Reconnaissance complete, they return home to sharpen their plans. A target is singled out for the kill—and if all goes well, Cray Research Inc. has sold another multimillion dollar supercomputer. This is the company’s newest sales hit team, comprising 60 of the company’s best salespeople, engineers, and scientists. Dubbed the “Industry, Science & Technology” department and created only last year, the team’s goal is to expand Cray’s market significantly beyond its traditional stake in the government defense sector to com panies and universities—and the strategy appears to be working.

Thanks in large part to this group’s ability to convince scientists that they need supercomputers, Cray is completing delivery and testing of an unprecedented 27 $2.5 million to $20 million machines in the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies